Anthropic Enters Drug R&D: Targeting Neglected Disease Areas
Anthropic announced it will personally conduct drug R&D, focusing on diseases traditionally neglected by pharmaceutical companies due to limited commercial returns. Its new platform, Claude Science, can rapidly analyze rare disease data, but experts point out that AI cannot replace lengthy experimental and regulatory processes. #AIDrugDiscovery
Return to original text
A short introduction is retained here; the full text from the source website is not reposted. For specific wording and subsequent updates, please refer to the original article.
Open the original article on ITHome